Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Busy address KBO
18 other companies have their registered office at the same address; threshold 10.
Financials
Financial year 2025
VERTEX PHARMACEUTICALS (BELGIUM) from Brussel, company number BE0781749031, closed financial year 2025 with a result of € 1.6 million after tax. For that financial year VERTEX PHARMACEUTICALS (BELGIUM) recorded revenue of € 88.9 million and equity of € 3.4 million. Compared with financial year 2024, the result moved from € 1.8 million to € 1.6 million. The company is profitable. The buffer is growing. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on June 29, 2026.
€ 3.4 million
▲ 87% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 1.6 million
▼ 12% vs 2024
Profit after tax over the fiscal year.
€ 28.1 million
▲ 30% vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 3.4 million.
People and assets in 2025
13.2
▲ 1 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 4.5 million
▲ 15% vs 2024
€ 344,000 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 84,260
▲ 23% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 48.5 million
▲ 41% vs 2024
Loans from banks and other lenders, long and short.
€ 29.6 million
Supplier invoices still open on the last day of the fiscal year. Pays suppliers within 133 days on average.
€ 603,261
▼ 26% vs 2024
Wages, holiday pay and social contributions still to pay. No outstanding taxes.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Revenue | - | - | € 80,178,082 | € 88,909,868 | ▲ 11% |
| Gross margin | - | € 5,106,592 | - | - | |
| Profit after taxes | € -598 | € 1,603,115 | € 1,818,556 | € 1,593,889 | ▼ 12% |
| Equity | € 19,402 | € 1,622,518 | € 1,841,074 | € 3,434,963 | ▲ 87% |
| Total debts | € 0 | € 42,985,250 | € 71,200,133 | € 80,771,564 | ▲ 13% |
| Cash | € 19,402 | € 7,920,080 | € 21,663,357 | € 28,140,485 | ▲ 30% |
| Retained profit | € -598 | € 1,602,518 | € 1,821,074 | € 3,414,963 | ▲ 88% |
| Dividend | € 0 | € 0 | € 1,600,000 | € 0 | ▼ 100% |
| Bank debt | € 0 | € 0 | € 34,285,633 | € 48,486,934 | ▲ 41% |
| Balance sheet total | € 19,402 | € 44,607,767 | € 73,240,146 | € 84,405,466 | ▲ 15% |
| Employees (FTE) | - | 9.3 | 12.2 | 13.2 | ▲ 1 |
Key figures of VERTEX PHARMACEUTICALS (BELGIUM), fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to VERTEX PHARMACEUTICALS (BELGIUM)?
What happened at VERTEX PHARMACEUTICALS (BELGIUM) in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 1.6 million (▼ 12% vs 2024). Source: NBB ↗
- Omar White became a director. NBB
- Prasanna Thombre became a director. NBB
- New establishment in Brussel. KBO
- Maryse Le Hur-Gurunlian became a director. NBB
- Start of the company according to the CBE. KBO
In short
From € 598 loss in 2022 to € 1.6 million profit in 2025.
Paid € 1.8 million in corporate taxes since 2022.
Best year ever: 2024, with € 1.8 million profit.
On average € 549,100 of value added per employee in 2023.
A new publication or filing at VERTEX PHARMACEUTICALS (BELGIUM)? We notify you, reason included.
Follow VERTEX PHARMACEUTICALS (BELGIUM)Databakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind VERTEX PHARMACEUTICALS (BELGIUM) are Maryse Le Hur-Gurunlian, Prasanna Thombre and Omar White. The shares are held by Vertex Pharmaceuticals (Europe) Limited (100%).
Directors
According to the 2025 annual accounts
Maryse Le Hur-Gurunlian
Director
since 2022
Prasanna Thombre
Director
since 2025
Omar White
Director
since 2025
Shareholders
Vertex Pharmaceuticals (Europe) Limited
100%
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Montoyerstraat 47
1000 Brussel
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 18 companies are registered at this address.
All companies at this address →Groupement des Relamineurs Belges du Fer et de l'Acier
CENTRE DES METAUX NON FERREUX - CENTRUM VAN DE NON FERRO METALEN
RESEAU EUROPEEN DE COOPERATION POUR LA RECHERCHE ET LE DEVELOPPEMENT : FUTURA
APCO WORLDWIDE
€ 12 million revenue · 2025
Blue Fish Europe
+13 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Website
Technologies
Hosting & Email
Email provider
Self-hosted
Hosting
AKAMAI-ASN1, NL
Domain
Domain
vrtx.com
Registered
2000-01-08
Registrar
CSC Corporate Domains, Inc.
Expires
2027-01-08
Website info
Features
Security
Network
Details
- Company number
- 0781.749.031
- VAT number
- BE 0781.749.031
- Registered office
- Montoyerstraat 47, 1000 Brussel
- Names & denominations
- VERTEX PHARMACEUTICALS (BELGIUM)
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 8 February 2022
- Peppol
- Active · Active since 1 Jan 2001
- Contact
- vrtx.com
- Activities · NACE
Groothandel in farmaceutische en medische artikelen
Detailhandel in farmaceutische producten